clinical trial · NCT07332533
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
Shanghai JMT-Bio Inc.·phase3·not yet recruiting·n = 490
HER2-positive Gastric CancerKN026CapecitabineEnlonstobartOxaliplatinTrastuzumabPembolizumabCisplatinFluorouracil
brief summary
This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer.
started
Dec 30, 2025
primary completion
Jun 30, 2032
completion
Dec 31, 2032
last updated
Jan 12, 2026
official title
A Phase II/III Study of KN026 Combined Chemotherapy With or Without Enlonstobart as First-line Treatment in HER2-positive Unresectable Locally Advanced or Metastatic Gastric Cancer.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol